Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

Rémi Forrat; Gustavo H. Dayan; Carlos A. DiazGranados; Matthew Bonaparte; Thelma Laot; Maria Rosario Capeding; Leilani Sanchez; Diana Leticia Coronel; Humberto Reynales; Danaya Chansinghakul; Sri Rezeki S. Hadinegoro; Ana Paula Perroud; Carina Frago; Betzana Zambrano; Tifany Machabert; Yukun Wu; Alexander Luedtke; Brenda Price; Claire Vigne; Owen Haney; Stephen J. Savarino; Alain Bouckenooghe; Fernando Noriega

doi:10.1093/cid/ciab288

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

Rémi Forrat, Gustavo H. Dayan, Carlos A. DiazGranados, Matthew Bonaparte, Thelma Laot, Maria Rosario Capeding, Leilani Sanchez, Diana Leticia Coronel, Humberto Reynales, Danaya Chansinghakul, Sri Rezeki S. Hadinegoro, Ana Paula Perroud, Carina Frago, Betzana Zambrano, Tifany Machabert, Yukun Wu, Alexander Luedtke, Brenda Price, Claire Vigne, Owen HaneyStephen J. Savarino, Alain Bouckenooghe, Fernando Noriega

Department of Pediatric

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (

Original language	English
Pages (from-to)	1003-1012
Number of pages	10
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	73
Issue number	6
DOIs	https://doi.org/10.1093/cid/ciab288
Publication status	Published - 15 Sep 2021

Keywords

CYD-TDV
dengue
serostatus
VCD

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciab288

Cite this

Forrat, R., Dayan, G. H., DiazGranados, C. A., Bonaparte, M., Laot, T., Capeding, M. R., Sanchez, L., Coronel, D. L., Reynales, H., Chansinghakul, D., Hadinegoro, S. R. S., Perroud, A. P., Frago, C., Zambrano, B., Machabert, T., Wu, Y., Luedtke, A., Price, B., Vigne, C., ... Noriega, F. (2021). Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(6), 1003-1012. https://doi.org/10.1093/cid/ciab288

Forrat, Rémi ; Dayan, Gustavo H. ; DiazGranados, Carlos A. ; Bonaparte, Matthew ; Laot, Thelma ; Capeding, Maria Rosario ; Sanchez, Leilani ; Coronel, Diana Leticia ; Reynales, Humberto ; Chansinghakul, Danaya ; Hadinegoro, Sri Rezeki S. ; Perroud, Ana Paula ; Frago, Carina ; Zambrano, Betzana ; Machabert, Tifany ; Wu, Yukun ; Luedtke, Alexander ; Price, Brenda ; Vigne, Claire ; Haney, Owen ; Savarino, Stephen J. ; Bouckenooghe, Alain ; Noriega, Fernando. / Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 ; Vol. 73, No. 6. pp. 1003-1012.

@article{5a48530834204e4c97edf58e973c5657,

title = "Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America",

abstract = "BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (",

keywords = "CYD-TDV, dengue, serostatus, VCD",

author = "R{\'e}mi Forrat and Dayan, {Gustavo H.} and DiazGranados, {Carlos A.} and Matthew Bonaparte and Thelma Laot and Capeding, {Maria Rosario} and Leilani Sanchez and Coronel, {Diana Leticia} and Humberto Reynales and Danaya Chansinghakul and Hadinegoro, {Sri Rezeki S.} and Perroud, {Ana Paula} and Carina Frago and Betzana Zambrano and Tifany Machabert and Yukun Wu and Alexander Luedtke and Brenda Price and Claire Vigne and Owen Haney and Savarino, {Stephen J.} and Alain Bouckenooghe and Fernando Noriega",

year = "2021",

month = sep,

day = "15",

doi = "10.1093/cid/ciab288",

language = "English",

volume = "73",

pages = "1003--1012",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

Forrat, R, Dayan, GH, DiazGranados, CA, Bonaparte, M, Laot, T, Capeding, MR, Sanchez, L, Coronel, DL, Reynales, H, Chansinghakul, D, Hadinegoro, SRS, Perroud, AP, Frago, C, Zambrano, B, Machabert, T, Wu, Y, Luedtke, A, Price, B, Vigne, C, Haney, O, Savarino, SJ, Bouckenooghe, A & Noriega, F 2021, 'Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 73, no. 6, pp. 1003-1012. https://doi.org/10.1093/cid/ciab288

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. / Forrat, Rémi; Dayan, Gustavo H.; DiazGranados, Carlos A.; Bonaparte, Matthew; Laot, Thelma; Capeding, Maria Rosario; Sanchez, Leilani; Coronel, Diana Leticia; Reynales, Humberto; Chansinghakul, Danaya; Hadinegoro, Sri Rezeki S.; Perroud, Ana Paula; Frago, Carina; Zambrano, Betzana; Machabert, Tifany; Wu, Yukun; Luedtke, Alexander; Price, Brenda; Vigne, Claire; Haney, Owen; Savarino, Stephen J.; Bouckenooghe, Alain; Noriega, Fernando.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 73, No. 6, 15.09.2021, p. 1003-1012.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

AU - Forrat, Rémi

AU - Dayan, Gustavo H.

AU - DiazGranados, Carlos A.

AU - Bonaparte, Matthew

AU - Laot, Thelma

AU - Capeding, Maria Rosario

AU - Sanchez, Leilani

AU - Coronel, Diana Leticia

AU - Reynales, Humberto

AU - Chansinghakul, Danaya

AU - Hadinegoro, Sri Rezeki S.

AU - Perroud, Ana Paula

AU - Frago, Carina

AU - Zambrano, Betzana

AU - Machabert, Tifany

AU - Wu, Yukun

AU - Luedtke, Alexander

AU - Price, Brenda

AU - Vigne, Claire

AU - Haney, Owen

AU - Savarino, Stephen J.

AU - Bouckenooghe, Alain

AU - Noriega, Fernando

PY - 2021/9/15

Y1 - 2021/9/15

N2 - BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (

AB - BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (

KW - CYD-TDV

KW - dengue

KW - serostatus

KW - VCD

UR - http://www.scopus.com/inward/record.url?scp=85116958578&partnerID=8YFLogxK

U2 - 10.1093/cid/ciab288

DO - 10.1093/cid/ciab288

M3 - Article

C2 - 33822015

AN - SCOPUS:85116958578

VL - 73

SP - 1003

EP - 1012

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -

Forrat R, Dayan GH, DiazGranados CA, Bonaparte M, Laot T, Capeding MR et al. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Sep 15;73(6):1003-1012. https://doi.org/10.1093/cid/ciab288

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this